somapacitan sold brand name sogroya growth hormone somapacitan human growth hormone somapacitanbeco produced escherichia coli recombinant dna common side effects include back pain joint paint indigestion sleep disorder dizziness tonsillitis swelling arms lower legs vomiting adrenal insufficiency hypertension increase blood creatine phosphokinase type enzyme weight increase approved medical use united states august european union march somapacitan first human growth hormone hgh therapy adults take week injection skin fdaapproved hgh formulations adults growth hormone deficiency must administered contains small noncovalent moiety reversibly binds serum albumin slows somapacitan indicated replacement endogenous growth hormone adults growth hormone deficiency ghd condition body doesnt produce enough growth hormone growth hormone regulates many functions body including accumulation fat trunk central area body associated serious medical somapacitan used people active malignancy stage diabetic eye disease high blood sugar levels cause damage blood vessels retina acute critical illness acute respiratory failure increased risk mortality use pharmacologic doses somapacitan critically ill individuals without growth hormone somapacitan evaluated randomized doubleblind placebocontrolled trial participants growth hormone deficiency never received growth hormone treatment stopped treatment growth hormone formulations least three months participants randomly assigned receive injections weekly somapacitan weekly placebo inactive treatment daily somatropin fdaapproved growth effectiveness somapacitan determined percentage change truncal fat fat accumulated trunk central area body regulated growth hormone associated serious medical trial conducted sites countries united states australia germany india japan latvia lithuania malaysia poland romania russian fed south africa sweden turkey ukraine united adult participants assigned random weekly sogroya placebo injections neither participants investigators knew treatment given end one additional group participants ghd received daily injections somatotropin approved treatment end treatment period truncal fat decreased average among participants taking weekly somapacitan increased among participants taking placebo daily somatropin group truncal fat decreased participants weekly somapacitan daily somatropin groups similar improvements clinical somapacitan approved medical use united states august us food drug administration fda granted approval sogroya novo nordisk january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product sogroya intended treatment growth hormone deficiency applicant medicinal product novo nordisk somapacitan approved medical use european union march antagonists pegvisomant httpsenwikipediaorgwikisomapacitan